InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,252.40
(
0.40%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.93
(
0.88%
)
Bitcoin
61,421.74
(
-0.63%
)
Post# of 252359
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: Robert C Jonson post# 157549

Wednesday, 02/27/2013 12:00:10 PM

Wednesday, February 27, 2013 12:00:10 PM

Post# of 252359

The folks in the treatment arm have an MOS of 11.7 months, longer than any other trial to date.



Yes, longer than any other trial to date except...

- Coley Pharma's CPG 7909 which showed 12.3 months median survival in a 2:1 randomized 121 patient trial.

- This study shows that pemetrexed and docetaxel show 11.7 and 12.2 months respectively.

- Gemcitabine maintenance, 12.1 months median survival

- Here's another one testing gefitinib vs pemetrexed, with median survival of 22.2 versus 18.9 months.


The last three trials I linked through Pubmed were just a scan of trials published from December 2012 through today.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up